0001415889-24-005883.txt : 20240229
0001415889-24-005883.hdr.sgml : 20240229
20240229162639
ACCESSION NUMBER: 0001415889-24-005883
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240227
FILED AS OF DATE: 20240229
DATE AS OF CHANGE: 20240229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paolini John F.
CENTRAL INDEX KEY: 0001741533
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38492
FILM NUMBER: 24704129
MAIL ADDRESS:
STREET 1: C/O KINIKSA PHARMACEUTICALS, LTD.
STREET 2: CLARENDON HOUSE, 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
FORMER NAME:
FORMER CONFORMED NAME: Paolini John
DATE OF NAME CHANGE: 20180522
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd.
CENTRAL INDEX KEY: 0001730430
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
BUSINESS PHONE: 7814399100
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
4
1
form4-02292024_090213.xml
X0508
4
2024-02-27
0001730430
Kiniksa Pharmaceuticals, Ltd.
KNSA
0001741533
Paolini John F.
C/O KINIKSA PHARMACEUTICALS, LTD.
CLARENDON HOUSE 2 CHURCH STREET
HAMILTON
D0
HM 11
BERMUDA
false
true
false
false
CHIEF MEDICAL OFFICER
1
Class A Common Share
2024-02-27
4
M
0
10156
1.86
A
55048
D
Class A Common Share
2024-02-27
4
S
0
10156
21.03
D
44892
D
Share Option
1.86
2024-02-27
4
M
0
10156
0
D
2026-09-13
Class A Common Shares
10156
101061
D
This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.00 to $21.09. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
The option is fully vested and exercisable.
/s/ Madelyn Zeylikman, Attorney-in-Fact
2024-02-29